Conventional orthopedics is excellent at imaging, immobilizing, and replacing what's worn out. Regenerative medicine asks a different question: can the underlying biology be reactivated? Here's what the science currently supports, and what we use at Innovita Clinic to put it to work.
By Jed Ryan, Founder and CEO · Reviewed by Adas Darinskas, PhD, Chief Science Officer · Published · Last reviewed
Musculoskeletal conditions are the slow-burn problems of the structural body: joints, cartilage, tendons, ligaments, intervertebral discs, and the connective tissue that ties them together. Most don't arrive overnight. They build over years of mechanical load, micro-injury, and the gradual decline of the cellular machinery that's supposed to be repairing all of it in the background.
For the patients we work with, the cluster includes:
These conditions look structurally different on imaging, but they share a common biological fingerprint underneath. That shared biology is where regenerative medicine has something to offer. Not as a replacement for orthopedic care, but as a different angle of approach.
Whether the entry point is a torn meniscus, a worn-out hip, or a chronically painful tendon, the same four systems are usually failing. Targeting them is the basis of every regenerative protocol.
The tissue is stuck in a perpetually slightly-inflamed state. Inflammatory cytokines like IL-1β, IL-6, and TNF-α stay elevated long after any acute injury, accelerating cartilage breakdown and suppressing the local cells that should be rebuilding it.
The scaffolding that holds tissue together (collagen, proteoglycans, hyaluronic acid) breaks down faster than it gets replaced. Cartilage thins. Tendons fray. Disc tissue dehydrates and loses height.
Resident stem cell populations (chondroprogenitors in cartilage, tenocytes in tendons, stem cells in the disc nucleus) decline in number and activity with age, injury, and chronic inflammation. The local repair capacity shrinks at exactly the moment it's needed most.
The cells still present in the tissue lose energetic capacity. Chondrocytes and myocytes with sluggish mitochondria can't synthesize matrix proteins efficiently, can't sustain repair under load, and tip into senescence, which accelerates the degenerative cycle.
Anti-inflammatories quiet the first system temporarily. Joint replacements solve the structural endpoint when the second has gone too far. Neither addresses systems three or four. Regenerative medicine targets all four at once.
There's no magic step here. The treatments we coordinate work through well-characterized cellular mechanisms: the same ones the body uses when it successfully repairs young, well-perfused tissue on its own.
Mesenchymal stem cells (MSCs) and the exosomes they secrete shift the local immune environment from pro-inflammatory toward resolution. Macrophages polarize from M1 (inflammatory) toward M2 (repair-supportive). Cytokine profiles change measurably within days.
MSCs don't necessarily transform into new cartilage themselves. Their primary effect is the cocktail of growth factors, cytokines, and exosomes they release into the surrounding tissue: TGF-β for matrix synthesis, VEGF for new blood-vessel growth, IGF-1 for cell survival, and dozens of others. The tissue starts repairing itself because the chemistry around it changed.
A subset of administered MSCs do home to injured tissue, engraft, and contribute directly to repair. The proportion is small relative to the paracrine effect, but in heavily depleted tissue (advanced osteoarthritis, chronic tendinopathy) the cellular contribution matters.
MSCs can quiet an overactive local immune response without broadly suppressing immunity the way long-term steroids or biologics do. For inflammatory and post-surgical cases, that distinction is significant.
Specific peptides, particularly BPC-157 and TB-500, accelerate angiogenesis and collagen deposition in tendon, ligament, and post-surgical tissue. They extend the regenerative window during the weeks after the cellular work is done.
These are the mechanisms behind healthy repair. Regenerative medicine reintroduces those signals to tissue that's lost the ability to generate them on its own.
The specific protocol our medical team designs for any given patient depends on tissue, severity, and history. But the building blocks below are the ones most often used for musculoskeletal cases, and each is chosen for a reason.
An advanced class of mesenchymal stem cells with a stress-enduring property: they survive the inflammatory, hypoxic, low-pH environment of damaged joint and tendon tissue, where conventional MSCs often die before they can work. They home to injury, modulate inflammation, and contribute to matrix repair through both paracrine signaling and direct differentiation.
Learn MoreStem-cell-derived nanoparticles that carry the regenerative messaging without the cells themselves. Smaller than MSCs, they diffuse through dense connective tissue more readily, reaching areas hard to inject directly. Often layered with cellular therapy or used alone in chronic tendinopathy and stubborn soft-tissue cases.
Learn MoreTwo of the best-characterized regenerative peptides for musculoskeletal indications. BPC-157 supports tendon, ligament, and gut healing through angiogenesis and growth-factor expression. TB-500 (thymosin beta-4) accelerates cell migration and tissue repair. Typically run as a defined-duration cycle following the in-clinic cellular work.
Learn MoreBirth-tissue-derived biologics, rich in the proteins, cytokines, and growth factors the body uses to restore tissue. Layered alongside the cellular work to reinforce the regenerative signal, particularly in heavily degraded joints and tendons where the local repair environment is depleted.
Learn MoreFor most musculoskeletal cases the protocol layers these: a localized MSC injection paired with systemic IV cellular delivery, exosomes added on the same day, peptide cycles continuing at home, and metabolic IVs supporting the days that matter most. The mix is built around your specific case, not a template.
Strong Craft Regen maintains a continuously updated repository of peer-reviewed research on regenerative medicine: the studies, mechanisms, and ongoing investigations that inform every protocol we coordinate.
Explore the Research